Navigation Links
Charleston Laboratories, Inc. Phase I Clinical Trial
Date:1/12/2009

Charleston begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108

CHARLESTON, S.C., Jan. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the initiation of a pharmacokinetic study on its first drug candidate, CL-108. "After many months' development in the lab, resulting in the optimal formulation of this drug, it is ready for testing in man," said Dr. Bernard Schachtel, Chief Medical Officer at Charleston Laboratories. "This Phase I study is being conducted to identify and characterize the release characteristics of CL-108, showing its differences (and similarities) to comparator drugs. We expect that the in-vivo results from this study will confirm the in-vitro results on CL-108, which can be advanced to the Phase III efficacy and safety trial we discussed with the FDA at our Pre-IND Meeting."

In fact, Dr. Schachtel added, "When the results of the Phase I study are available (in early 2009), Charleston Labs will be ready to test the efficacy and safety of CL-108 in patients with acute pain. Charleston Labs' Phase III study on CL-108 is already in the planning stages," he said. "Clinical investigators have been selected at major U.S. universities to conduct this large study beginning in 2009."

"We are looking forward to achieving the expected results of our fast dissolving low dose anti-emetic," said Paul Bosse, Chief Executive Officer at Charleston Laboratories. "CL-108 is the first of many planned therapeutic products Charleston is advancing into clinical studies." Reaching this exciting milestone is a testament of perseverance and dedication by the entire Charleston team."

All clinical studies for Charleston Laboratories are being overseen by SRC, Inc., a contract research organization based in Jupiter, Florida that is renowned for its clinical trials on patients' symptoms (such as nausea and vomiting) and its record of drug approvals by regulatory authorities in the U.S. and worldwide.

About Charleston Laboratories, Inc.

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Doug Flutie, Jr. Foundation Grants NAA $10,000 for Burbacher/Charleston Study
2. The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients
3. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
7. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
8. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
9. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
10. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Biscom Document Router (BDR), the first IoT device from Biscom designed to deliver ... Biscom will debut BDR at HIMSS17 and will be conducting demonstrations ...
(Date:2/20/2017)... ... February 20, 2017 , ... Houston dentist ... emergency dental care at his office, Antoine Dental Center. Emergency dentistry encompasses many ... they are at risk for serious complications and often experience severe pain. Not ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks ... was facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... in better care, and MEDfx and the Delaware Health Information Network (DHIN) have ... As the nation’s first state-wide health information exchange, DHIN stores and shares real-time ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken ... Stairlift and other Butler products. Ken was impressed with the safety and reliability ... endorse the product on his show. This endorsement by Ken Matthews can be ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Fla. , Feb. 20, 2017   ... helping physicians diagnose and treat patients with cardiovascular ... provide wireless connectivity for ZywiePro, Zywie,s cardiac remote ... AT&T Control Center . AT&T and ... monitoring for those with the disease. The Internet ...
(Date:2/20/2017)... 20, 2017 Seal Shield LLC ( ... for mobile device management and disinfection, the ElectroClave™, to ... Exhibition in Orlando, Fla. from ... devices have become commonplace in today,s healthcare landscape, but ... of concerns, including the disinfection and tracking of these ...
(Date:2/20/2017)... DUBLIN , Feb. 20, 2017 Research ... Blood Refrigerator and Freezer Market Analysis and Trends - Product (RFID ... - Forecast to 2025" report to their offering. ... The Global RFID Blood ... of around 21.3% from 2015 to 2025. This ...
Breaking Medicine Technology: